Cogent Biosciences 公司在2026年美国临床肿瘤学会年会上,公布了其PEAK III期试验的详细临床数据。该试验评估了Bezuclastinib与舒尼替尼联合疗法,用于治疗胃肠道间质瘤患者的疗效与安全性。
Cogent Biosciences 公司在2026年美国临床肿瘤学会年会上,公布了其PEAK III期试验的详细临床数据。该试验评估了Bezuclastinib与舒尼替尼联合疗法,用于治疗胃肠道间质瘤患者的疗效与安全性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.